Pharmaceutical firm Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) has been selected in India’s immunisation programme in selected states.

Globally, pneumococcal disease is one of the leading causes of deaths in children younger than five years.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to 2015 Farooqui article, nearly 105,000 children succumbed to pneumococcal pneumonia in India in 2010.

In the first phase, the programme will include nearly 5.15 million babies in India, which is approximately 20% of India’s total birth cohort.

Pfizer India manager S Sridhar said: “The Government of India has made reaching every child with vaccines as a key priority.

See Also:

“With the introduction of PCV 13, we will able to help protect India’s birth cohort of 26 million children from the leading cause of child deaths in the country.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"With the introduction of PCV 13, we will able to help protect India’s birth cohort of 26 million children from the leading cause of child deaths in the country."

“Pfizer remains committed to supporting the government and its partners in expanding the introduction of PCV 13 in the country, so much that every child in India gets access to protection from pneumococcal diseases.”

Pfizer noted that PCV 13, one of the widely used pneumococcal conjugate vaccines, is deployed in more than 100 countries’ immunisation programme and includes a majority of serotype coverage that are prevalent in India.

Epidemiological studies carried out in India have confirmed the effectiveness of the PCV 13.

The vaccine will be introduced in a multi-dose vial format in the country and has been specially designed by Pfizer to improve the effectiveness of public immunisation programmes.

During the first phase, PCV 13 will be supplied directly by Pfizer through UNICEF.